Compare Quest Diagnostics Inc (DGX) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while Direxion Daily S&P 500 Bull 3X Shares trades at $298.44 (market cap $7.36B). The key difference: Quest Diagnostics Inc is far larger — about 3.5× Direxion Daily S&P 500 Bull 3X Shares's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Direxion Daily S&P 500 Bull 3X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Direxion Daily S&P 500 Bull 3X Shares for 32 Days on average.
| DGX | SPXL | |
|---|---|---|
Market Cap | $25.48B | $7.36B |
Volume | 941,866 | 1,835,467 |
Sector | Health | Leveraged / Inverse |
52-Week High | $247.45 | $301.38 |
52-Week Low | $173.49 | $170.20 |
Typical Hold Time | 56 Days | 32 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
SPXL trades at $297.97, up 0.38% with a bullish technical signal from moving averages. The ETF shows neutral oscillator readings with RSI at 66.91 suggesting mild overbought conditions. Support levels begin at $289 with resistance at $297. Recent news highlights S&P 500 valuation debates and profit growth expectations shifting from 35% in 2026 to 15% in 2027.
Outlook remains cautiously optimistic given the ETF's leveraged exposure to S&P 500 momentum. Key risks include market concentration in top holdings and potential profit growth deceleration. The technical setup favors continued upside if $297 resistance breaks, while failure to hold $289 support could signal near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
